ClinicalTrials.gg
RecruitingNCT07915245Updated Nov 18, 2026

A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy

A Phase 1 interventional study of LY4247147 and LY4247147 in Obesity and Overweight, sponsored by Eli Lilly and Company. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Updated Nov 18, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 118 studies in Obesity by Eli Lilly and Company — 30 open to participants now, 54 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.

Planned enrollment
93rd of 117
108 · median 267
Started
2026
with 24 others
Phase 1
40 of 118
8 open now
Primary completion
2028-10
later than 45 of 53 live
Registered
118th of 118
by date

Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 93rd largest by planned enrollment of the 117 interventional ones that give a count, is one of 25 that started in 2026, is one of 40 in phase 1, reaches primary completion later than 45 of the 53 other live ones, and was the 118th registered.

Obesity

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

30 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Obesity by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to understand how safe and well-tolerated LY4247147 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4247147 gets into the bloodstream and how long it takes the body to eliminate it.

The study will be conducted in 3 parts. For each participant in Parts A and C, the study will last about 30 weeks and will include a stay in the Clinical Research Unit (CRU) lasting about 8 nights. For each participant in Part B, the study will last about 39 weeks and will include up to 3 stays in the CRU lasting about 9 nights each.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy with no comorbidities related to (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease.
  • Have overweight with a BMI of greater than or equal to (≥) 27 kilograms per square meter (kg/m²).
  • Have obesity with a BMI of ≥30 kg/m2.
  • Have had a self-reported stable weight for 3 months prior to screening.
  • Singapore only: Participants must be 21 to 65 years of age.

Exclusion criteria

Exclusion Criteria:

  • Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data.
  • Is an individual of (IOCBP).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    LY4247147 Part A

    LY4247147 administered subcutaneously (SC)

    Drug: LY4247147

  • Placebo comparator
    Placebo Part A

    Placebo administered SC

    Drug: Placebo

  • Experimental
    LY4247147 Part B

    LY4247147 administered SC

    Drug: LY4247147

  • Placebo comparator
    Placebo Part B

    Placebo administered SC

    Drug: Placebo

  • Experimental
    LY4247147 Part C

    LY4247147 administered intravenously (IV)

    Drug: LY4247147

Interventions

  • DrugLY4247147

    administered SC

  • DrugLY4247147

    administered IV

  • DrugPlacebo

    administered SC

06

What researchers measure

Primary outcomes

  1. Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Baseline through End of the Follow-up (Estimated as Week 25)

  2. Part B: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Baseline through End of the Follow-up (Estimated as Week 33)

Secondary outcomes

  1. Part A and C: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4247147

    Time frame: Predose on Day 1 through Week 25

  2. Part B: PK: Cmax of LY4247147

    Time frame: Predose on Day 1 through Week 33

  3. Part A: PK: Time of Maximum Observed Drug Concentration (Tmax) of LY4247147

    Time frame: Predose on Day 1 through Week 25

  4. Part B: PK: Tmax of LY4247147

    Time frame: Predose on Day 1 through Week 33

  5. Part A and C: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4247147

    Time frame: Predose on Day 1 through Week 25

  6. Part B: PK: AUC of LY4247147

    Time frame: Predose on Day 1 through Week 33

07

Study locations

1 of 3 sites recruiting
  • ICON Early Phase Services Lenexa Center
    Lenexa, Kansas 66219, United States
    Recruiting
    • · Contact913-410-2973
    • DANIEL DICKERSON · Principal investigator
  • ICON
    Salt Lake City, Utah 84124, United States
    Not yet recruiting
    • · Contact801-904-4514
    • Konstantin Malley · Principal investigator
  • Lilly Centre for Clinical Pharmacology
    Singapore, 138623, Singapore
    Not yet recruiting
    • · Contact64139811
    • Jennifer Boon Wee · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Oct 2028, 23 months after the start.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 23 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 4, 2026
StartActual
Nov 6, 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
Show 3 sites
  • ICON Early Phase Services Lenexa Center · Lenexa, United Statesno status→Recruiting
  • ICON · Salt Lake City, United Statesno status→Not yet recruiting
  • Lilly Centre for Clinical Pharmacology · Singapore, Singaporeno status→Not yet recruiting
Nov 18, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • ICON Early Phase Services Lenexa Center · Lenexa, United StatesContact person changed (no phone or email listed)Contact •••2485→•••2973
Nov 18, 2026
Registered
First appeared on the registry
Nov 4, 2026
Show all 2 updates
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
    Show 3 sites
    • ICON Early Phase Services Lenexa Center · Lenexa, United Statesno status→Recruiting
    • ICON · Salt Lake City, United Statesno status→Not yet recruiting
    • Lilly Centre for Clinical Pharmacology · Singapore, Singaporeno status→Not yet recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • ICON Early Phase Services Lenexa Center · Lenexa, United StatesContact person changed (no phone or email listed)Contact •••2485→•••2973
    + 2 other changes: verification date and date precision
  2. Nov 4, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07915245
Responsible party
Sponsor
First posted
Nov 4, 2026
Start date
Nov 6, 2026
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion